SCHEMBL4326122

SCHEMBL4326122

Cc1ccsc1C(=O)Nc1cc(CN2CCN(CCO)CC2)ccc1/C=C/c1n[nH]c2ccccc12

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 7/20 0.74
AURKB Q96GD4 6/20 0.74
CDK5 Q00535 1/20 0.39
CDK5R1 Q15078 1/20 0.39
FGFR1 P11362 1/20 0.39
FLT1 P17948 1/20 0.39
HTR1A P08908 1/20 0.38
DRD2 P14416 1/20 0.38
HTR2A P28223 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
NTRK1 P04629 2/20 0.37
MAP4K4 O95819 1/20 0.37
FLT3 P36888 1/20 0.37
GFER P55789 1/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4326126 1.00 AURKA (0.74) AURKAAURKBCDK5CDK5R1FGFR1
SCHEMBL4313646 0.96 AURKA (0.72) AURKAAURKBCDK5CDK5R1FGFR1
SCHEMBL4313639 0.96 AURKA (0.72) AURKAAURKBCDK5CDK5R1FGFR1
SCHEMBL4313197 0.95 AURKA (0.74) AURKAAURKBCDK5CDK5R1FGFR1
SCHEMBL4313205 0.95 AURKA (0.74) AURKAAURKBCDK5CDK5R1FGFR1
SCHEMBL4315050 0.93 AURKA (0.69) AURKAAURKBCDK5CDK5R1FGFR1
SCHEMBL4315046 0.93 AURKA (0.69) AURKAAURKBCDK5CDK5R1FGFR1
SCHEMBL4324732 0.93 AURKA (0.70) AURKAAURKBCDK5CDK5R1FGFR1
SCHEMBL14989352 0.93 AURKB (0.70) AURKAAURKBCDK5CDK5R1FGFR1
SCHEMBL4324741 0.93 AURKA (0.70) AURKAAURKBCDK5CDK5R1FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1847532-B1 IGF-1R INHIBITOR KYOWA HAKKO KIRIN CO LTD (JP) 2013-06-05 EP claimed
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US claimed
EP-1847532-B1 IGF-1R INHIBITOR KYOWA HAKKO KIRIN CO LTD (JP) 2013-06-05 EP disclosed
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 AURKA 3687/4885AURKB 3438/4885CDK5 816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.